Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

Share Price is delayed by 15 minutes
Get Live Data
2,209.00    19.00 (0.87%)
Bid:
2,212.00
Ask:
2,214.00
Spread: 2.00 (0.09%)
Market Cap: £22.41b
III Live PriceLast checked at - London Stock Exchange

Intraday 3i Group Share Chart

FY2019 Q1 performance update

25 Jul 2018 07:00

RNS Number : 6483V
3i Group PLC
25 July 2018
 

25 July 2018

 

3i Group plc

FY2019 Q1 performance update

 

A good start to the year

 

· NAV per share of 760 pence and total return of 5.1% for the three months to 30 June 2018

 

· Cash realisations of £337 million in the quarter, net of the £535 million reinvestment in Scandlines

 

· Completed two new Private Equity investments in Royal Sanders and International Cruise and Excursions ("ICE") totalling £245 million

 

· Advised 3i Infrastructure plc ("3iN") on its investment in Attero and a further investment for Infinis, Alkane Energy

 

Simon Borrows, Chief Executive, commented:

 

"This was another productive quarter for 3i with good portfolio performance as well as significant investment and realisation activity. We completed the Group's sale and reinvestment into Scandlines, two new Private Equity investments and advised 3iN on its investments in Attero and Alkane Energy. Our balance sheet is strong but we remain cautious about the pricing of new investments in the current environment. Overall, our portfolio of international companies remains well positioned, despite the macro uncertainties, to deliver another year of good earnings growth."

 

 

Private Equity

Portfolio performance

The Private Equity portfolio generated good returns in the quarter. The majority of the portfolio performed well with notable value growth increases from Action, Basic-Fit, Cirtec Medical and Etanco.

 

Private Equity investments

We completed our £135 million investment in Royal Sanders, a private label and contract manufacturing producer of personal care products, in April 2018. In June 2018, we completed our £110 million investment in ICE, a global travel and loyalty company that connects leading brands, travel suppliers and end consumers. In addition to our proprietary investment, we continue to originate acquisition opportunities for our portfolio companies. In the quarter, Royal Sanders announced its first acquisition under our ownership and there is a good pipeline of other acquisition opportunities across the portfolio, the majority of which are expected to be funded by the companies themselves.

 

 

Private Equity realisations

We generated total cash proceeds in the quarter of £868 million, principally from the £835 million received from the sale of Scandlines in June 2018, before taking account of the Group's £535 million reinvestment.

 

Private Equity

 Realisation proceeds

 

£m

Full realisations

 

 

Scandlines1

835

 

SLR

30

Partial realisations

 

 

Other

3

Total Q1 2019 cash proceeds

868

1. Private Equity proceeds are shown gross and before the Group's £535 million reinvestment.

In June 2018, we announced the realisation of Etanco, one of the last investments in Eurofund V, for proceeds of c.€102 million. At 30 June 2018, Etanco was held on an imminent sales basis and valued at £88 million, an uplift of 32% compared to its value at 31 March 2018 of £66 million.

 

Infrastructure

Our Infrastructure team had a busy start to the year, including advising 3iN on the completion of its investments in Attero and Alkane Energy and its refinancing of TCR. 3iN's shares performed well in the quarter, generating unrealised value growth of £27 million for 3i in addition to dividend income of £11 million.

The infrastructure market remains very active and our Infrastructure team is working on a pipeline of interesting investment opportunities in Europe and North America.

Total return and NAV position

 

We recognised a £99 million gain on foreign exchange in the quarter, as both the US dollar and euro strengthened against sterling. Based on the balance sheet at 30 June 2018, a 1% movement in the euro and US dollar would result in a total return movement of £47 million and £10 million respectively. The diluted NAV per share increased to 760 pence (31 March 2018: 724 pence) or 738 pence after deducting the 22p per share FY2018 dividend, which was paid on 20 July 2018.

Balance sheet

 

Top 10 investments by value at 30 June 2018

 

 

 

Valuation

Valuation

 

 

Valuation

Valuation

Mar-18

Jun-18

 

 

basis

currency

£m

£m

Activity in the quarter

Action

Earnings

EUR

2,064

2,215

 

3i Infrastructure plc

Quoted

GBP

581

604

Ex-dividend 14 June 2018

Scandlines

Price of recent investment

EUR

803

539

Full realisation and 3i's partial reinvestment completed on 21 June 2018 and generated net proceeds of £300m

Basic-Fit

Quoted

EUR

270

334

 

Weener Plastics

Earnings

EUR

244

248

 

Audley Travel

Earnings

GBP

233

238

 

Q Holding

Earnings

USD

229

235

 

Cirtec Medical

Earnings

USD

190

219

 

Hans Anders

Earnings

EUR

189

191

 

Smarte Carte

DCF

USD

167

179

Received refinancing proceeds of £4m

The 10 investments in this table comprise 72% (31 March 2018: 75%) of the total Proprietary Capital portfolio value of £6,915 million (31 March 2018: £6,657 million).

 

Balance sheet

 

At 30 June 2018, the Group's balance sheet included net cash of £638 million, before the 22 pence FY2018 dividend (£213 million), which was paid on 20 July 2018.

 

- ENDS -

 

Notes

 

1.

Balance sheet values are stated net of foreign exchange translation. Where applicable, the GBP equivalents at 30 June in this update have been calculated at a currency exchange rate of €1.1310:£1 and $1.3201:£1 respectively. At 30 June 2018, 64% of the Group's net assets were in euro and 14% were in US dollar.

2.

At 30 June 2018 3i had 973 million diluted shares.

3.

Action was valued using a post discount run-rate EBITDA multiple of 16.5x based on its run-rate earnings to 30 June 2018.

 

 

For further information, please contact:

Silvia SantoroInvestor Relations DirectorTel: 020 7975 3258

Kathryn van der Kroft

Communications DirectorTel: 020 7975 3021

 

About 3i Group

3i is a leading international investment manager focused on mid-market Private Equity and Infrastructure. Our core investment markets are northern Europe and North America. For further information, please visit: www.3i.com.

 

All statements in this performance update relate to the three month period ended 30 June 2018 unless otherwise stated. The financial information is unaudited and is presented on 3i's non-GAAP Investment basis in order to provide users with the most appropriate description of the drivers of 3i's performance. Net asset value ("NAV") and total return are the same on the Investment basis and on an IFRS basis. Details of the differences between 3i's consolidated financial statements prepared on an IFRS basis and under the Investment basis are provided in the 2018 Annual report and accounts. There have been no material changes to the financial position of 3i from the end of this quarter to the date of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUSUBRWNABUAR
Date   Source Headline
5th Jun 20264:00 pmRNSHolding(s) in Company
2nd Jun 20264:24 pmRNSDirector/PDMR Shareholding
2nd Jun 20263:37 pmRNSDirector/PDMR Shareholding - Amendment
1st Jun 20264:28 pmRNSDirector/PDMR Shareholding
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20265:42 pmRNSTotal Voting Rights
29th May 20265:38 pmRNSAdmission to Trading
27th May 202610:42 amRNSNotice of AGM
26th May 20267:00 amRNSTransaction in Own Shares
22nd May 202612:29 pmRNSDirector/PDMR Shareholding
21st May 20267:40 amRNSDoc re. 2026 Annual Report and Accounts
19th May 20262:28 pmRNSDirector/PDMR Shareholding
18th May 20267:00 amRNSTransaction in Own Shares
15th May 202610:24 amRNSDirector/PDMR Shareholding
14th May 202610:41 amRNSHolding(s) in Company
14th May 20267:02 amRNSCommencement of Share Buyback Programme
14th May 20267:00 amRNSResults for the year to 31 March 2026
1st May 202612:00 pmRNSDirector/PDMR Shareholding
30th Apr 20263:34 pmRNSTotal Voting Rights
30th Apr 20263:31 pmRNSAdmission to Trading
7th Apr 202612:33 pmRNSHolding(s) in Company
1st Apr 20269:53 amRNSPortfolio Update
1st Apr 20269:36 amRNSDirector/PDMR Shareholding
31st Mar 20262:30 pmRNSTotal Voting Rights
31st Mar 20262:29 pmRNSAdmission to Trading
31st Mar 202611:37 amRNSDirector/PDMR Shareholding
30th Mar 20267:00 amRNSDirector/PDMR Shareholding
27th Mar 20263:07 pmRNSAdmission to Trading
26th Mar 20267:00 amRNSAction Capital Markets Seminar & portfolio update
23rd Mar 202612:11 pmRNSHolding(s) in Company
2nd Mar 202612:18 pmRNSDirector/PDMR Shareholding
27th Feb 20264:00 pmRNSTotal Voting Rights
3rd Feb 202610:20 amRNSHolding(s) in Company
3rd Feb 202610:17 amRNSDirector Declaration
30th Jan 20262:24 pmRNSDirector/PDMR Shareholding
30th Jan 20261:47 pmRNSTotal Voting Rights
29th Jan 202612:19 pmRNSDirector/PDMR Shareholding
29th Jan 20267:00 amRNSFY2026 Q3 performance update
7th Jan 20262:06 pmRNSDirector/PDMR Shareholding
6th Jan 20261:53 pmRNSTotal Voting Rights
2nd Jan 202611:06 amRNSPortfolio Update
9th Dec 20251:11 pmRNSBlock listing Interim Review
4th Dec 20252:12 pmRNSDirector/PDMR Shareholding
1st Dec 20251:25 pmRNSDirector/PDMR Shareholding
28th Nov 20254:24 pmRNSTotal Voting Rights
20th Nov 20259:59 amRNSDirector/PDMR Shareholding
18th Nov 20252:23 pmRNSDirector/PDMR Shareholding
17th Nov 202512:50 pmRNSDirector/PDMR Shareholding
17th Nov 202512:48 pmRNSDirector/PDMR Shareholding
14th Nov 20254:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.